Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMMU Immunomedics (IMMU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Immunomedics Stock (NASDAQ:IMMU) 30 days 90 days 365 days Advanced Chart Ad DTIIntrigued by massive crypto wins - but too afraid to take the risk? Are you intrigued by the massive wins cryptocurrencies can bring in, but too afraid to take the risk? After all… There's no denying trading Bitcoin and other Cryptocurrencies are some of the most high-risk trades you can place. But what if there was a way to target those massive gains, without even touching a single risky coin? I'm talking about gains as big as… Thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! Click here for a FREE workshop and discover one trader’s $213,000 real-money trade! Get Immunomedics alerts:Sign Up Key Stats Today's Range$87.86▼$87.8650-Day Range$85.08▼$87.8652-Week Range$8.80▼$87.93VolumeN/AAverage Volume4.01 million shsMarket Capitalization$20.31 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewImmunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.Read More… Intrigued by massive crypto wins - but too afraid to take the risk? (Ad)Are you intrigued by the massive wins cryptocurrencies can bring in, but too afraid to take the risk? After all… There's no denying trading Bitcoin and other Cryptocurrencies are some of the most high-risk trades you can place. But what if there was a way to target those massive gains, without even touching a single risky coin? I'm talking about gains as big as… Thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! Click here for a FREE workshop and discover one trader’s $213,000 real-money trade! Receive IMMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMU Stock News HeadlinesGilead to pull drug that had won conditional approval for bladder cancerOctober 18, 2024 | bizjournals.comAntibody Drug Conjugates Market Size Potential to Reach USD 39 Billion by 2032 By IMIR Market Research Pvt. Ltd.October 7, 2024 | finance.yahoo.comKickstart your own Weekend Side Hustle right from your couch Today I want to show you how to start your very own Weekend Side Hustle right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.October 30, 2024 | DTI (Ad)TROP2 Antibody Market & Clinical Trials Report to 2029: Insight By Company, Country, Indication & Phase - ResearchAndMarkets.comAugust 23, 2024 | businesswire.comNew treatment option for endometrial cancer shows promise in phase II trialAugust 1, 2024 | msn.comGilead Sciences's Options Frenzy: What You Need to KnowJuly 31, 2024 | benzinga.comA Look At Gilead Sciences After Its Recent WeaknessJuly 27, 2024 | seekingalpha.comDecoding Gilead Sciences Inc (GILD): A Strategic SWOT InsightMay 9, 2024 | finance.yahoo.comSee More Headlines IMMU Stock Analysis - Frequently Asked Questions How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to analysts' expectations of $24.81 million. What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunomedics investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Gilead Sciences (GILD) and Meta Platforms (META). Company Calendar Last Earnings8/05/2020Today10/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryBiotechnology Current SymbolNASDAQ:IMMU CUSIP45290710 CIK722830 Webwww.immunomedics.com Phone973-605-8200FaxN/AEmployees366Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-357,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.40% Return on Assets-51.32% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.58 Sales & Book Value Annual Sales$290,000.00 Price / Sales70,028.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book63.67Miscellaneous Outstanding Shares231,144,000Free FloatN/AMarket Cap$20.31 billion OptionableOptionable Beta2.90 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:IMMU) was last updated on 10/30/2024 by MarketBeat.com Staff From Our PartnersThis biotech's ONE drug could change medicine as we know itThis Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses...Smallcaps Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | SponsoredCentral banks prepare for America’s Breaking PointIf you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredA Gold Storm Is ComingStrange new catalyst for gold ($5,000 possible?) Many are wondering why so many countries are frantically b...Stansberry Research | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunomedics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.